Professor Robert Jones
Professor and Consultant in Medical Oncology
- JonesRH7@cardiff.ac.uk
- +44 29208 79035
- Sir Martin Evans Building, Museum Avenue, Cardiff, CF10 3AX
- Media commentator
Overview
Publication
2023
- Kristeleit, R. et al. 2023. A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. British Journal of Cancer (10.1038/s41416-023-02279-x)
- Jones, R. et al. 2023. A Phase I/II trial of Oral SRA737 (a Chk1 Inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer. Clinical Cancer Research 29(2), pp. 331-340. (10.1158/1078-0432.CCR-22-2074)
2022
- Saad, F. et al. 2022. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. The Lancet Oncology 23(10), pp. 1297-1307. (10.1016/S1470-2045(22)00498-3)
- Banerjee, S. et al. 2022. A phase I trial of CT900, a novel α-folate receptor-mediated thymidylate synthase inhibitor, with expansion cohorts in patients with high grade serous ovarian cancer. Clinical Cancer Research 22, article number: 1268. (10.1158/1078-0432.CCR-22-1268)
- Howell, S. J. et al. 2022. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. The Lancet Oncology 23(7), pp. 851-864. (10.1016/s1470-2045(22)00284-4)
2021
- Seligmann, J. F. et al. 2021. Inhibition of WEE1 is effective in TP53- and RAS-mutant metastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring. Journal of Clinical Oncology 39(33), pp. 3705-3715. (10.1200/JCO.21.01435)
- Arana Echarri, A. et al. 2021. A phenomic perspective on factors influencing breast cancer treatment: integrating aging and lifestyle in blood and tissue biomarker profiling. Frontiers in Immunology 11, article number: 616188. (10.3389/fimmu.2020.616188)
2020
- Jones, R. H. et al. 2020. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncology 21(3), pp. 345-347. (10.1016/S1470-2045(19)30817-4)
- Hong, D. S. et al. 2020. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clinical Cancer Research 26(6), pp. 1220-1228. (10.1158/1078-0432.CCR-19-2962)
- Peltola, K. J. et al. 2020. ODM-204, a novel dual Inhibitor of CYP17A1 and androgen receptor: early results from phase I dose escalation in men with castration-resistant prostate cancer. European Urology Focus 6(1), pp. 63-70. (10.1016/j.euf.2018.08.022)
2019
- de Bono, J. S. et al. 2019. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncology 20(3), pp. 383-393. (10.1016/S1470-2045(18)30859-3)
2018
- Basu, B. et al. 2018. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals of Oncology 29(9), pp. 1918-1925. (10.1093/annonc/mdy245)
- Clarke, N. et al. 2018. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology 19(7), pp. 975-986. (10.1016/S1470-2045(18)30365-6)
2017
- Garcia Martin, I., Janssen, A., Jones, R., Grimstead, J. W., Penketh, R. J. A., Baird, D. M. and John, R. M. 2017. Telomere length heterogeneity in placenta revealed with high-resolution telomere length analysis. Placenta 59, pp. 61-68. (10.1016/j.placenta.2017.09.007)
- Scurr, M. et al. 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial. JAMA Oncology 3(10), article number: e172579. (10.1001/jamaoncol.2017.2579)
- Scurr, M. J. et al. 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research, article number: clincanres.0895.2017. (10.1158/1078-0432.CCR-17-0895)
- Scurr, M. et al. 2017. MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. Journal of Clinical Oncology 35(7), pp. 154-154. (10.1200/JCO.2017.35.7_suppl.154)
2016
- Reza, M. et al. 2016. Bone scan index and progression-free survival data for progressive metastatic castration-resistant prostate cancer patients who received ODM-201 in the ARADES multicentre study. European Urology Focus 2(5), pp. 547-552. (10.1016/j.euf.2016.01.005)
2014
- Fizazi, K. et al. 2014. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncology 15(9), pp. 975-985. (10.1016/S1470-2045(14)70240-2)
- Greenow, K. R., Clarke, A. R., Williams, G. T. and Jones, R. 2014. Wnt-driven intestinal tumourigenesis is suppressed by Chk1 deficiency but enhanced by conditional haploinsufficiency. Oncogene 33, pp. 4089-4096. (10.1038/onc.2013.371)
2009
- Greenow, K. R., Clarke, A. R. and Jones, R. H. 2009. Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation. Oncogene 28(11), pp. 1443-1453. (10.1038/onc.2008.482)
2006
- Robinson, H. M. R., Jones, R. H., Walker, M., Zachos, G., Brown, R., Cassidy, J. and Gillespie, D. A. F. 2006. Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene 25(39), pp. 5359-5369. (10.1038/sj.onc.1209532)
2004
- Jones, R. H., Reubi, J., Millan, D. and Vasey, P. 2004. Octreotide: an active agent in epithelial ovarian carcinoma?. The Lancet Oncology 5(4), pp. 251-253. (10.1016/S1470-2045(04)01430-5)
2003
- Jones, R. H. and Vasey, P. A. 2003. Part II: Testicular cancer - management of advanced disease. The Lancet Oncology 4(12), pp. 738-747. (10.1016/S1470-2045(03)01279-8)
- Jones, R. H., Goldstein, D., Kurtovic, J., Keogh, G. and Riordan, S. M. 2003. Compression of liver parenchyma by a malignant hepatic cyst a previously unreported manifestation of metastatic gastric cancer [Letter]. The American Journal of Gastroenterology 98(5), pp. 1211-1213. (10.1016/S0002-9270(03)00170-9)
- Jones, R. H., Ryan, M. and Friedlander, M. 2003. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. Gynecologic Oncology 89(1), pp. 112-115. (10.1016/S0090-8258(03)00066-0)
- Jones, R. H. and Vasey, P. A. 2003. New directions in testicular cancer; molecular determinants of oncogenesis and treatment success. European Journal of Cancer 39(2), pp. 147-156. (10.1016/S0959-8049(02)00612-3)
2001
- Twelves, C. and Jones, R. H. 2001. Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil?. Expert Opinion on Pharmacotherapy 2(9), pp. 1495-1505. (10.1517/14656566.2.9.1495)
1990
- Millar, J. B., McGowan, C. H., Lenaers, G., Jones, R. and Russell, P. 1990. p80cdc25 mitotic inducer is the tyrosine phosphatase that activates p34cdc2 kinase in fission yeast. Embo Journal 10(13), pp. 5610-5621.
1989
- Jones, R. and Jones, N. C. 1989. Mammalian cAMP-responsive element can activate transcription in yeast and binds a yeast factor(s) that resembles the mammalian transcription factor ATF. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 86(7), pp. 2176-2180.
1988
- Jones, R., Moreno, S., Nurse, P. and Jones, N. C. 1988. Expression of the SV40 promoter in fission yeast: identification and characterization of an AP-1-like factor. Cell 53(4), pp. 659-667. (10.1016/0092-8674(88)90581-8)
Articles
- Kristeleit, R. et al. 2023. A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. British Journal of Cancer (10.1038/s41416-023-02279-x)
- Jones, R. et al. 2023. A Phase I/II trial of Oral SRA737 (a Chk1 Inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer. Clinical Cancer Research 29(2), pp. 331-340. (10.1158/1078-0432.CCR-22-2074)
- Saad, F. et al. 2022. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. The Lancet Oncology 23(10), pp. 1297-1307. (10.1016/S1470-2045(22)00498-3)
- Banerjee, S. et al. 2022. A phase I trial of CT900, a novel α-folate receptor-mediated thymidylate synthase inhibitor, with expansion cohorts in patients with high grade serous ovarian cancer. Clinical Cancer Research 22, article number: 1268. (10.1158/1078-0432.CCR-22-1268)
- Howell, S. J. et al. 2022. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. The Lancet Oncology 23(7), pp. 851-864. (10.1016/s1470-2045(22)00284-4)
- Seligmann, J. F. et al. 2021. Inhibition of WEE1 is effective in TP53- and RAS-mutant metastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring. Journal of Clinical Oncology 39(33), pp. 3705-3715. (10.1200/JCO.21.01435)
- Arana Echarri, A. et al. 2021. A phenomic perspective on factors influencing breast cancer treatment: integrating aging and lifestyle in blood and tissue biomarker profiling. Frontiers in Immunology 11, article number: 616188. (10.3389/fimmu.2020.616188)
- Jones, R. H. et al. 2020. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncology 21(3), pp. 345-347. (10.1016/S1470-2045(19)30817-4)
- Hong, D. S. et al. 2020. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clinical Cancer Research 26(6), pp. 1220-1228. (10.1158/1078-0432.CCR-19-2962)
- Peltola, K. J. et al. 2020. ODM-204, a novel dual Inhibitor of CYP17A1 and androgen receptor: early results from phase I dose escalation in men with castration-resistant prostate cancer. European Urology Focus 6(1), pp. 63-70. (10.1016/j.euf.2018.08.022)
- de Bono, J. S. et al. 2019. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncology 20(3), pp. 383-393. (10.1016/S1470-2045(18)30859-3)
- Basu, B. et al. 2018. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals of Oncology 29(9), pp. 1918-1925. (10.1093/annonc/mdy245)
- Clarke, N. et al. 2018. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology 19(7), pp. 975-986. (10.1016/S1470-2045(18)30365-6)
- Garcia Martin, I., Janssen, A., Jones, R., Grimstead, J. W., Penketh, R. J. A., Baird, D. M. and John, R. M. 2017. Telomere length heterogeneity in placenta revealed with high-resolution telomere length analysis. Placenta 59, pp. 61-68. (10.1016/j.placenta.2017.09.007)
- Scurr, M. et al. 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial. JAMA Oncology 3(10), article number: e172579. (10.1001/jamaoncol.2017.2579)
- Scurr, M. J. et al. 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research, article number: clincanres.0895.2017. (10.1158/1078-0432.CCR-17-0895)
- Scurr, M. et al. 2017. MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. Journal of Clinical Oncology 35(7), pp. 154-154. (10.1200/JCO.2017.35.7_suppl.154)
- Reza, M. et al. 2016. Bone scan index and progression-free survival data for progressive metastatic castration-resistant prostate cancer patients who received ODM-201 in the ARADES multicentre study. European Urology Focus 2(5), pp. 547-552. (10.1016/j.euf.2016.01.005)
- Fizazi, K. et al. 2014. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncology 15(9), pp. 975-985. (10.1016/S1470-2045(14)70240-2)
- Greenow, K. R., Clarke, A. R., Williams, G. T. and Jones, R. 2014. Wnt-driven intestinal tumourigenesis is suppressed by Chk1 deficiency but enhanced by conditional haploinsufficiency. Oncogene 33, pp. 4089-4096. (10.1038/onc.2013.371)
- Greenow, K. R., Clarke, A. R. and Jones, R. H. 2009. Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation. Oncogene 28(11), pp. 1443-1453. (10.1038/onc.2008.482)
- Robinson, H. M. R., Jones, R. H., Walker, M., Zachos, G., Brown, R., Cassidy, J. and Gillespie, D. A. F. 2006. Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene 25(39), pp. 5359-5369. (10.1038/sj.onc.1209532)
- Jones, R. H., Reubi, J., Millan, D. and Vasey, P. 2004. Octreotide: an active agent in epithelial ovarian carcinoma?. The Lancet Oncology 5(4), pp. 251-253. (10.1016/S1470-2045(04)01430-5)
- Jones, R. H. and Vasey, P. A. 2003. Part II: Testicular cancer - management of advanced disease. The Lancet Oncology 4(12), pp. 738-747. (10.1016/S1470-2045(03)01279-8)
- Jones, R. H., Goldstein, D., Kurtovic, J., Keogh, G. and Riordan, S. M. 2003. Compression of liver parenchyma by a malignant hepatic cyst a previously unreported manifestation of metastatic gastric cancer [Letter]. The American Journal of Gastroenterology 98(5), pp. 1211-1213. (10.1016/S0002-9270(03)00170-9)
- Jones, R. H., Ryan, M. and Friedlander, M. 2003. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. Gynecologic Oncology 89(1), pp. 112-115. (10.1016/S0090-8258(03)00066-0)
- Jones, R. H. and Vasey, P. A. 2003. New directions in testicular cancer; molecular determinants of oncogenesis and treatment success. European Journal of Cancer 39(2), pp. 147-156. (10.1016/S0959-8049(02)00612-3)
- Twelves, C. and Jones, R. H. 2001. Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil?. Expert Opinion on Pharmacotherapy 2(9), pp. 1495-1505. (10.1517/14656566.2.9.1495)
- Millar, J. B., McGowan, C. H., Lenaers, G., Jones, R. and Russell, P. 1990. p80cdc25 mitotic inducer is the tyrosine phosphatase that activates p34cdc2 kinase in fission yeast. Embo Journal 10(13), pp. 5610-5621.
- Jones, R. and Jones, N. C. 1989. Mammalian cAMP-responsive element can activate transcription in yeast and binds a yeast factor(s) that resembles the mammalian transcription factor ATF. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 86(7), pp. 2176-2180.
- Jones, R., Moreno, S., Nurse, P. and Jones, N. C. 1988. Expression of the SV40 promoter in fission yeast: identification and characterization of an AP-1-like factor. Cell 53(4), pp. 659-667. (10.1016/0092-8674(88)90581-8)